Orchard Therapeutics PLC
Anne-Isabelle Prevot has extensive experience in regulatory affairs, with roles at companies like Orchard Therapeutics, Chugai Pharma Europe, Medpace, Servier, and Pfizer. Anne-Isabelle'sresponsibilities have included leading global regulatory strategy, defining and delivering regulatory strategies for early development, preparing regulatory submissions, and managing regulatory projects in areas such as gene therapy, cardiovascular field, and fixed-dose combinations.
Anne-Isabelle Prevot completed their Doctor of Pharmacy degree at Paris-Sud University (Paris XI) in 2007. Anne-Isabelle also obtained a Master's degree in 'Health Law, Regulatory Affairs' from the same university in the same year.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.